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The one‐stage factor VIII (FVIII) clotting assay measures the extent 
by which a plasma sample corrects the coagulation time of FVIII‐
deficient plasma in an activated partial thromboplastin time (aPTT)‐
based assay.1 The availability of this “surrogate” measure of FVIII 
activity has been the foundation of clinical diagnostics for hemo‐
philia as it can be used to establish a diagnosis of FVIII deficiency, 
assign severity, and identify the presence of neutralizing inhibitors.2 
Approximately three‐quarters of all clinical laboratories globally 
rely on the one‐stage aPTT‐based clotting assay to measure FVIII.3 
Other FVIII assays may be required for full diagnostic precision, such 
as chromogenic FVIII activity assays to accurately phenotype pa‐
tients with nonsevere hemophilia A.2
FVIII activity assays have also become a cornerstone for the 
management of hemophilia A, allowing for dose adjustment of FVIII 
replacement, monitoring of FVIII levels during treatment and pro‐
phylaxis, and optimization of FVIII dosing for pharmacokinetic (PK)‐
guided prophylaxis.4 In recent years, the recombinant platform has 
allowed for the bioengineering of FVIII with improved properties 
such as extended half‐life, reduced immunogenicity, and enhanced 
affinity for von Willebrand factor.5 The bioengineered FVIII mole‐
cules have posed some challenges because discrepancies have been 
observed between the one‐stage and the chromogenic assays, but 
these may be overcome with product‐specific standards.6,7 Where 
there may still be challenges in the interpretation of one‐stage and 
chromogenic FVIII assays, thrombin generation assays have also been 
used for monitoring FVIII replacement.8 However, the recent intro‐
duction of a novel therapeutic is changing the paradigm of reliance 
on these surrogate FVIII assays for the management of hemophilia.
Emicizumab‐kxwh (Hemlibra, F. Hoffmann–La Roche, Basel, 
Switzerland) is a humanized bispecific monoclonal antibody that 
substitutes for missing FVIIIa by bridging FIXa and FX to promote 
effective hemostasis in persons with hemophilia A.9 It has no 
sequence homology to FVIII and therefore does not induce FVIII 
inhibitors and its function is not impaired in the presence of FVIII in‐
hibitors. Emicizumab has a high bioavailability, allowing for subcuta‐
neous administration, and has a half‐life of approximately 30 days.10 
PK profiles demonstrate that, at steady‐state, trough levels can be 
maintained sufficient to provide effective bleed control with weekly, 
2‐weekly and 4‐weekly maintenance dosing regimens.11 As such, 
dosing regimens can be chosen based on patient and/or physician 
preference and pharmacokinetic monitoring is not required.
Does this new treatment paradigm mean that laboratory assays 
are no longer necessary when patients are on emicizumab prophy‐
laxis? Several management issues remain that could be addressed 
with another “surrogate” assay such as the one‐stage FVIII assay 
has served. There is evidence for interpatient variability of the peak 
and trough levels at steady state, although the clinical trials have 
not identified any significant correlation with clinical outcome mea‐
sures.10,12 However, a Japanese study in hemophilia with inhibitors 
showed a clinical improvement in four subjects with dose up‐titra‐
tion.13 Clinicians have 50 years of experience in the correlation of 
bleed control with FVIII levels in most every imaginable clinical sce‐
nario (e.g., minor and major surgery, trauma, central nervous sys‐
tem bleeding, use of concomitant anticoagulants). There may yet be 
some value in a similar correlation of bleeding control in such sce‐
narios with emicizumab prophylaxis within the range of inter‐ and 
intrapatient variability of their levels. More important, we do not 
have sufficient data on the PK profiles of the youngest infants and 
how that changes over time. This is an age group that represents a 
significant treatment gap because they are typically not placed on 
prophylaxis with FVIII replacement due to the challenges of intrave‐
nous infusions, and consequently may be one of the most significant 
beneficiaries of this therapy. In addition, antidrug antibodies, al‐
though they seem to occur infrequently with the use of emicizumab, 
can affect the clearance of the drug, or neutralize its function, either 
of which could impact bleed control.14 Given the vast clinical experi‐
ence with FVIII assays to date, it's not surprising that clinicians would 
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be looking for an assay of emicizumab that could provide some esti‐
mate of FVIII activity equivalence that could address these remain‐
ing management challenges.
The manuscript from Leksa et al15 is an excellent evaluation of 
the potential utility of coagulation assays that have been tradition‐
ally used for evaluating FVIII activity, including one‐stage clotting 
assays, chromogenic assays, and thrombin generation. They have 
prepared a sequence‐identical version of the commercially available 
bispecific antibody, emicizumab, as well as a novel bispecific anti‐
body bioengineered for more specificity in its affinity for FIXa and 
FX. They conclude that the significant differences in the mechanism 
of action of these bispecific antibodies (bsAbs) leads to a wide range 
of “FVIII‐like” activity readouts such that the utility of these assays 
to establish FVIII bioequivalence is limited.
This is not unexpected given that emicizumab and FVIII are fun‐
damentally different proteins and are regulated differently16: (a) 
FVIIIa has multiple sites of interaction with FIXa, FX, and the phos‐
pholipid surface, whereas emicizumab binds to single sites within 
FIX(a) and FX(a); (b) FVIII needs to be activated (thrombin medi‐
ated), emicizumab does not; (c) FVIII binds to von Willebrand factor, 
emicizumab does not; (d) FVIIIa binds to the phospholipid surface, 
emicizumab does not, and FVIIIa binding limits movement of the 
FX‐activating complex more than emicizumab; (e) FVIIIa binds to 
the surface of activated platelets, emicizumab probably does not; (f) 
FVIIIa has a much higher binding affinity for enzyme and substrate 
than emicizumab; (g) FVIIIa enhances FXa generation ~10‐fold over 
emicizumab; and (h) emicizumab can bind both activated and nonac‐
tivated forms of FIX and FX.17
The one‐stage aPTT‐based FVIII clotting assay has particular lim‐
itations. Similar to the observations within the preclinical evaluation 
and clinical trial program with emicizumab, Leksa and colleagues show 
that the clotting time is maximally shortened by the bsAbs with no ev‐
idence for a dose response. The kinetic advantage of the bsAbs leads 
to this significant overestimation of the FVIII activity. This also has im‐
plications for evaluating for FVIII inhibitors while on emicizumab be‐
cause the Bethesda assay is typically performed with an aPTT‐based 
clotting assay. Given the reliance of most clinical laboratories on these 
assays, it is likely that patients on emicizumab may still have these 
assays performed, with misleading results and potential adverse impli‐
cations for clinical care, even though appropriate guidance is provided 
in the prescribing information. They next show that a chromogenic 
FVIII assay that uses human reagents detects the procoagulant effect 
of the bsAbs; however, the purified reagents include only FIXa, thus 
this assay does not evaluate any impact of bsAb affinity for unacti‐
vated FIX. In addition, the FVIII and bsAb dose‐response curves lack 
parallelism and do not scale proportionately, limiting the ability for 
this assay to be used to establish FVIII bioequivalence. Finally, they 
show that the thrombin generation assay has multiple variables that 
can limit the ability of this global assay to assign FVIII bioequivalence: 
the triggering reagent, phospholipid concentration, and multiple read‐
out parameters that do not yet have clinical correlates with hemo‐
static protection from clinical trials. Notably, each of these assays rely 
on the fact that FVIIIa is the limiting factor, whereas levels of FIXa 
are in excess over FVIIIa. In assays with bsAbs, FIXa also becomes a 
limiting component. FIXa levels can differ strongly from one assay to 
the other, which may contribute to the challenge of establishing FVIII 
equivalence.
The extensive clinical trial program for emicizumab demonstrated 
that it can be used safely with high efficacy without the need for lab‐
oratory monitoring while on prophylactic dosing. Nevertheless, some 
useful recommendations for the use of laboratory assays have been 
adopted. A chromogenic‐based Bethesda assay that uses bovine re‐
agents has been demonstrated to allow for measurement of FVIII in‐
hibitors18 and though not widely available, is now offered nationally to 
clinicians in the United States through the laboratory at the Centers 
for Disease Control and Prevention. Chromogenic FVIII assays that 
use bovine reagents can also be used to assay the FVIII activity of 
any additional FVIII concentrate administered or endogenous FVIII. 
Alternatively, a chromogenic FVIII assay that uses human reagents 
could be used to follow emicizumab activity for evaluation of PK, to 
correlate with clinical outcomes, monitor for changes in peak/trough 
levels over time, or to evaluate any apparent loss of efficacy. However, 
the widely available conventional aPTT and clot‐based FVIII activity 
assays can still be used in evaluating a case of loss of efficacy. The 
aPTT should be within the normal range in all persons with hemophilia 
when obtained during ongoing treatment with emicizumab; there‐
fore, a prolonged aPTT assay and/or a low one‐stage FVIII activity in 
a person treated with emicizumab would be a useful initial evaluation 
for the presence of a neutralizing antidrug antibody directed against 
emicizumab.
The manuscript from Leksa et al,15 although highlighting the 
challenges for assigning FVIII bioequivalence with currently avail‐
able clinical assays, provides important biochemical insights into 
the mechanism of action of bsAbs and their impact on the kinetics 
of coagulation. This should help support the development of novel 
clinical assays, not to derive FVIII bioequivalence, but rather to es‐
tablish a benchmark “surrogate” activity that can be correlated with 
clinically relevant outcomes in hemophilia, just as we did for FVIII 
in the past.
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